Treace Medical Concepts (NASDAQ:TMCI) Announces Earnings Results

Treace Medical Concepts (NASDAQ:TMCI) announced its quarterly earnings results on Thursday. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03, Zacks reports. Treace Medical Concepts had a negative return on equity of 51.12% and a negative net margin of 30.33%. Treace Medical Concepts updated its FY 2025 guidance to EPS.

Treace Medical Concepts Stock Down 5.9 %

TMCI stock traded down $0.57 during trading on Thursday, reaching $9.13. 694,852 shares of the stock were exchanged, compared to its average volume of 727,345. The firm’s 50 day moving average is $8.83 and its 200 day moving average is $7.19. Treace Medical Concepts has a twelve month low of $3.92 and a twelve month high of $14.09. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51. The firm has a market cap of $568.77 million, a P/E ratio of -9.22 and a beta of 0.75.

Wall Street Analyst Weigh In

Several research firms recently issued reports on TMCI. Truist Financial raised their price target on Treace Medical Concepts from $7.00 to $8.40 and gave the company a “hold” rating in a report on Wednesday, December 18th. BTIG Research upgraded Treace Medical Concepts from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Tuesday, February 4th. Lake Street Capital assumed coverage on Treace Medical Concepts in a research note on Tuesday, December 31st. They set a “buy” rating and a $14.50 target price for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $8.00 price objective on shares of Treace Medical Concepts in a report on Tuesday, December 17th. Finally, Stifel Nicolaus boosted their price target on Treace Medical Concepts from $7.00 to $8.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Treace Medical Concepts currently has an average rating of “Hold” and an average target price of $9.99.

About Treace Medical Concepts

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.